Vectura Group Plc (VEC) - Medical Equipment - Deals and Alliances Profile
October 2018
55
About the Report
About the Report
Summary
Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases. The company develops products based on a wide range of proprietary lung delivery technologies, including device and formulation capabilities. Vectura has a varied portfolio of drugs in clinical development, comprising several novel and generic programs that are partnered with several global biotechnology and pharmaceutical companies. Vectura is headquartered in Chippenham, Wiltshire, the UK.
Vectura Group Plc (VEC)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Vectura Group Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vectura Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Vectura Group Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Vectura Group Plc, Medical Equipment, Deal Details 11
Asset Purchase 11
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 11
Partnerships 12
Ablynx Exercises Option for Licensing Agreement with Vectura 12
Vectura Enters into Agreement with Dynavax Technologies 13
Vectura Enters into Co-Development Agreement with Propeller Health 14
Activaero Enters Into Distribution Agreement With Vivisol For Akita Jet Inhalation System 15
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 16
Activaero Enters Into Co-Development Agreement With TransMIT 17
Merger 18
SkyePharma Merges with Vectura 18
Equity Offering 20
SkyePharma Completes Private Placement Of Shares For USD 187 Million 20
SkyePharma Completes Rights Offering Of Shares 21
Vectura Group Completes Private Placement Of Shares For USD 46 Million 22
Acquisition 23
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 23
Vectura Acquires Activaero, Medical Device Company, For USD 181 Million 24
Vectura Group Plc-Key Competitors 26
Vectura Group Plc-Key Employees 27
Vectura Group Plc-Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Sep 11, 2018: Vectura Group: Interim Results 29
Mar 21, 2018: Vectura Group: 2017 Preliminary Results 38
Mar 21, 2018: Vectura Group: 2017 Preliminary Results-Performance in-line with expectations, with strong in-market growth from key inhaled products 39
Sep 06, 2017: Vectura Group: 2017 Interim Results 41
Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 43
Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 45
Corporate Communications 46
Jul 16, 2018: Vectura Appoints Paul Fry as Chief Financial Officer and Executive Director 46
Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director 47
Apr 20, 2018: Vectura Announces Senior Management Change 48
Apr 20, 2018: Vectura Group: Directorate Change-Chief Financial Officer 49
Nov 29, 2017: Vectura Group appoints Juliet Thompson to its Board of Directors 50
Mar 06, 2017: Vectura Group: Board Change 51
Other Significant Developments 52
Feb 16, 2017: Vectura achieves GBP9 million royalty cap from GSK Ellipta products 52
Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach USD 512 million triggering USD 5 million milestone receipt 53
Jan 11, 2017: Vectura Group: Pre-close update 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Figure
List of Figures
Vectura Group Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Vectura Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Vectura Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Vectura Group Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Vectura Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Vectura Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List of Table
List of Tables
Vectura Group Plc, Medical Equipment, Key Facts, 2017 2
Vectura Group Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Vectura Group Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Deals By Market, 2012 to YTD 2018 9
Vectura Group Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 11
Ablynx Exercises Option for Licensing Agreement with Vectura 12
Vectura Enters into Agreement with Dynavax Technologies 13
Vectura Enters into Co-Development Agreement with Propeller Health 14
Activaero Enters Into Distribution Agreement With Vivisol For Akita Jet Inhalation System 15
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 16
Activaero Enters Into Co-Development Agreement With TransMIT 17
SkyePharma Merges with Vectura 18
SkyePharma Completes Private Placement Of Shares For USD 187 Million 20
SkyePharma Completes Rights Offering Of Shares 21
Vectura Group Completes Private Placement Of Shares For USD 46 Million 22
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 23
Vectura Acquires Activaero, Medical Device Company, For USD 181 Million 24
Vectura Group Plc, Key Competitors 26
Vectura Group Plc, Key Employees 27
Vectura Group Plc, Subsidiaries 28
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.